A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination with Nivolumab and/or Ipilimumab in Advanced Solid Tumors

Protocol: 
AAAQ8183
Phase: 
I/II

A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination with Nivolumab and/or Ipilimumab in Advanced Solid Tumors

Are you Eligible? (Inclusion Criteria)

1. Subjects must be at least 18 years old and have histologic or cytologic
confirmation of a
malignancy that is advanced (metastatic, recurrent and/or unresectable) with
measurable disease
per RECIST v1.1.
2. Eastern Cooperative Oncology Group (ECOG) performance status of <= 1.
3. Washout period of any time greater than 4 weeks from the last treatment,
specifically for
checkpoint pathway inhibitors.
4. Prior palliative radiotherapy must have been completed at least 2 weeks prior
to
first dose of study drug.

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States